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Introduction
• Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the highly contagious,
zoonotic virus responsible for the COVID-19 pandemic causes a wide range of potentially
chronic symptoms.
• Since the original Wuhan Strain, several SARS-CoV-2 variants have emerged, such as the
B.1.351 SARS-CoV-2 variant which first emerged in South Africa
• The Receptor Binding Domain (RBD), located within the Spike protein of SARS-CoV-2
serves as a highly immunogenic epitope for potent neutralizing antibodies.
• Current mRNA vaccines (Moderna and Pfizer-BioNTech) encode for the Spike protein of
SARS-CoV-2, which allows the body to build antigen-specific antibodies.
• To manage the COVID-19 pandemic, it is essential to develop serological assays which
measure protective antibody titers upon infection or vaccination.
• Serological assays which indicate presence and level of antibody protection against
SARS-CoV-2 can be used as a platform for variant screening.
• RBD-foldon 2.2 is a novel antigen produced by fusing RBD with the trimerization domain
Fibritin from Bacteriophage T4. Its amino acid sequence is based on the original Wuhan
Strand that was sequenced in Washington. (Breckenridge, 2021).
• B.1.351 RBD-foldon 2.2 antigen is identical to the RBD-foldon 2.2 antigen except it uses
the B.1.351 variant RBD sequence.
• Using cancer patient sera samples from the University of Louisville Co-Immunity study, the
breadth and robustness of response was examined in comparison to patients that
indicated “no chronic conditions”.
Figure 1. General Structure
of SARS-CoV-2 particle.
Includes four structural
proteins: the envelope
protein (E), nucleocapsid
protein (N), spike protein (S),
and membrane protein (M).
(Min & Sun)

Preliminary Data

Hypothesis

Significance

We hypothesize there will be a difference in humoral response
to RBD-variant antigens in COVID-19 vaccinated cancer
patients currently undergoing treatment versus patients with no
chronic conditions.

• Study will inform level of protection in immunocompromised
groups which may have a suppressed response after
vaccination.
• Variant screening essential to understand level of antibody
protection produced by Pfizer and Moderna vaccines.
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P= 0.78
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P= 0.29
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Conclusions
•

Methods
• Sample Selection: 36 cancer patients were age/sex matched to 36 individuals with no
underlying health conditions, that received the same mRNA vaccine within two weeks
of each other.
• ELISA End-point Titers: Sera samples were diluted 1:100 on an antigen-coated plate,
then diluted three-fold down each row of a 96-well plate. ELISAs included detection of
IgG and IgA antibodies against Spike, RBD-foldon, RBD-foldon 2.2, and RBD-foldon
resembling the B.1.351 variant. Signal was detected at 450 nm. Values were blank
subtracted, and the endpoint titer was determined with a cutoff of average negative
values. (Bushau, 2021).
• Statistical Analysis: Student’s t-test was used to compare the mean value of endpoint titers with a confidence interval of 95% between cancer patient group and patient
group with no chronic conditions/control.

P= 0.41
n=36
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RBD-foldon 2.2 Plasmid Design: Foldon nucleotide sequence was added to RBD nucleotide sequence
using a Proline-rich linker (previously used Glycine-Serine linker). RBD-foldon 2.2 also differed from the
initial RBD-foldon construct by a modified signal peptide sequence. Fused sequence was inserted into
Geneware® plasmid expression vector which encodes DNA for Tobacco Mosaic Virus (TMV), enabling
protein expression in plants. Plasmid Amplification: The plasmid was transformed in E. Coli bacteria,
then DNA was isolated (OMEGA Bio-Tek E.Z.N.A Plasmid DNA Midi Prep Kit). Amplified & prepped DNA
was transcribed into RNA. Infectious RNA was mixed with plant inoculation buffer for Nicotiana
benthamiana inoculation. Virion Extraction: Virion particles were extracted by Polyethylene Glycol
(PEG) precipitation. Samples were loaded onto an SDS-PAGE to confirm virion had been isolated and
TMV was expressed. RBD-foldon 2.2 Extraction and Purification: Plant extract was purified with an
Immobilized Metal Affinity Chromatography (IMAC) gravity-flow column. Final elution sample was buffer
exchanged using Ultrafiltration/Diafiltration (UF/DF) from imidazole containing buffer to 1x PBS so the
concentration of the RBD-foldon could be determined using a spectrophotometer. (Breckenridge, 2021)
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Fig. 2. RBD-foldon ELISA Layout (1°
Antibody: Human Sera anti-RBD, 2 °
Antibody: Rabbit anti-Human HRP
Conjugate, TMB: Reporter Enzyme)
(Joey Breckenridge Jr., M.S.)

There is no significant difference between cancer patients and age matched
controls for Spike IgG and IgA or RBD-foldon IgG and IgA.
There is no significant difference between cancer patients and patients with no
chronic conditions in response for variant B.1.351 RBD-foldon IgG and IgA.
RBD-foldon 2.2 elicits a lower humoral response than RBD-foldon, indicating the
edited linker affects how the antigen presents
B.1.351 RBD-foldon appears to elicit a lower response than RBD-foldon 2.2.

P= 0.47
n=12

Figure 3. Spike IgG. Mean and
standard deviation of reciprocal
endpoint titers with spike antigen and
IgG antibody. Figure 4. Spike IgA. Mean
and standard deviation of reciprocal
endpoint titers with Spike antigen and
IgA antibody. Figure 5. RBD-foldon IgG.
Mean and standard deviation of
reciprocal endpoint titers with RBDfoldon antigen and IgG antibody. Figure
6. RBD-foldon IgA. Mean and standard
deviation of reciprocal endpoint titers
with RBD-foldon antigen and IgA
antibody. Figure 7. RBD-foldon 2.2 IgG.
Mean and standard deviation of
reciprocal endpoint titers with RBDfoldon 2.2 antigen and IgG antibody.
Figure 8. RBD-foldon 2.2 IgA. Mean
and standard deviation of reciprocal
endpoint titers with RBD-foldon 2.2
antigen and IgA antibody. Figure 9.
B.1.351 RBD-foldon IgG. Standard
deviation of reciprocal endpoint titers
with B.1.351 RBD-foldon antigen and
IgG antibody. Figure 10. B.1.351 RBDfoldon IgA. Standard deviation of
reciprocal endpoint titers with B.1.351
RBD-foldon antigen and IgA antibody.
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